NCT00483860已完成1 期
A Phase I Study of Oral Topotecan in Subjects With Cancer and Impaired Renal Function
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 59
- 试验地点
- 1
- 主要终点
- Comparison of blood levels of topotecan following oral and IV dosing;
研究概览
简要总结
To determine the effect of renal impairment and prior platinum-based chemotherapy on the safety and blood levels of topotecan administered orally
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- •Age 18 years or older.
- •A performance status score of 0, 1, or 2 on the Eastern Cooperative Oncology Group (ECOG) Scale.
- •Histologically- or cytologically-confirmed advanced solid tumors.
- •Failed conventional therapy for their tumor type; or subjects who have a tumor type for which no standard effective therapy exists; or subjects for whom single-agent topotecan therapy is suitable.
- •Completion of a 24-hour urine collection within 14 days prior to the first dose to calculate the creatinine clearance value and determine the renal impairment category (refer to Appendix 8).
- •Using Cockcroft-Gault formula (refer to Appendix 6), documentation of stable renal function should be performed within 14 days of the first scheduled dose of study medication using at least 2 serum creatinine values separated by a minimum of 7 days. Stable renal function is defined as:
- •≤25% change for CrCl <40 mL/min or
- •≤10 mL/min change for CrCl ≥40 mL/min NOTE: Documentation of stable renal function will NOT be required if the 24-hour urine collection to determine the renal impairment category is completed within 7 days prior to the first dose.
排除标准
- •Currently undergoing dialysis.
- •Pregnant or lactating.
- •Women of childbearing potential who refuse to either abstain from sexual intercourse or practice adequate contraception
- •Male subjects with female partners of childbearing potential who have not had a prior vasectomy or if both the male subject and the female partner refuse to use adequate contraception beginning 14 days before exposure to study drug, continuing throughout the clinical trial, and for a period of 3 months after the last dose of study drug.
- •Uncontrolled emesis, regardless of etiology.
- •Bilirubin > 1.5 X ULN.
- •SGOT/AST, SGPT/ALT and alkaline phosphatase >2 times the upper limit of normal (ULN) if no evidence of potentially associated metastases (e.g., liver or bone) by computed tomography (CT) or magnetic resonance imaging (MRI). If potentially associated metastases (e.g., liver or bone) are present, subjects with <5 times ULN are eligible to participate, following discussion with and approval from a GSK Medical Monitor.
- •Hematological values outside of acceptable ranges. Active infection. Prior anti-cancer therapy, including, but not limited to, chemotherapy (except nitrosurea or mitomycin C), radiotherapy, biologic therapy, investigational therapy or major surgery within 21 days of the first scheduled dose of study drug. Prior nitrosurea of mitomycin C chemotherapy within 6 weeks of first scheduled dose of study drug. Failure to recover to Grade 1 or better from any toxicity (except alopecia) related to prior anti-cancer therapy by Day 1, Course 1 unless agreed to by a GSK Medical Monitor and the Investigator. Clinical evidence of a gastrointestinal (GI) condition (i.e., removal of a portion of the stomach, recent GI obstruction or GI neuropathy) or taking drugs that would alter GI absorption or motility. Currently taking or will require treatment with cyclosporin A. Concurrent severe medical problems unrelated to the malignancy, which would significantly limit full compliance with the study or expose the subject to extreme risk (including major surgery within 21 days or placement of biliary stents or nephrostomy tubes within 7 days). History of allergic reactions to topotecan or compounds chemically related to topotecan (e.g., irinotecan).
研究组 & 干预措施
Topotecan
Experimental
once a day
干预措施: Topotecan (Drug)
结局指标
主要结局
Comparison of blood levels of topotecan following oral and IV dosing;
时间窗: blood samples will be drawn on Day 1 and Day 8 of Courses 1 and 2.
次要结局
- Assessment of clinical laboratory tests, cardiac monitoring and disease progression. Comparison of blood levels of topotecan when taken orally with and without food;(blood samples will be drawn on Day 1)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Phase I Study of Oral Topotecan in Subjects with Cancer and Impaired Renal Functioelke uitgebreide solide tumorrenal impairement1002765610038430CancerNL-OMON30871GlaxoSmithKline12
已完成
1 期
Topotecan in Combination With Pemetrexed in Patients With Advanced MalignanciesEndometrial CancerLung CancerOvarian CancerCervical CancerNCT00315861SCRI Development Innovations, LLC15
已完成
1 期
A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy VolunteersRenal ImpairmentNCT01578928Novartis Pharmaceuticals50
已完成
1 期
To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal FunctionRenal ImpairmentNCT05404542Cerevel Therapeutics, LLC14
已完成
1 期
Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid TumorsSolid TumorsNCT00502892M.D. Anderson Cancer Center2